TJO-087

DRUG2 trials

Sponsors

Taejoon Pharmaceutical Co., Ltd.

Conditions

Dry Eye SyndromeDry Eye Syndrome (DES)

Phase 2

Evaluate the Safety and Efficacy of TJO-087

Active, not recruitingNCT07810972

Taejoon Pharmaceutical Co., Ltd.Dry Eye Syndrome (DES)

Start: 2026-04-06End: 2026-12-01Updated: 2026-09-09

Phase 3

Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients

Taejoon Pharmaceutical Co., Ltd.Dry Eye Syndrome

Start: 2020-06-19End: 2023-04-30Target: 182Updated: 2022-02-18

Related Papers

A Multicenter, Randomized, Double-Blind Evaluation of the Efficacy of TJO-087 Versus 0.05% Cyclosporine A in Moderate to Severe Dry Eye

Journal of Ocular Pharmacology and Therapeutics2022-11-3016 citations